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ABSTRACT
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely
achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a
promising approach for the treatment of hematologic malignancies.
We investigated the efficacy of CD19xCD3 DART bispecific antibody in a broad panel of human
primary B-cell malignancies. The CD19xCD3 DART identified 2 distinct subsets of patients, in which
the neoplastic lymphocytes were eliminated with rapid or slow kinetics. Delayed responses were
always overcome by a prolonged or repeated DART exposure. Both CD4 and CD8 effector cytotoxic
cells were generated, and DART-mediated killing of CD4C cells into cytotoxic effectors required the
presence of CD8C cells. Serial exposures to DART led to the exponential expansion of CD4C and CD8C
cells and to the sequential ablation of neoplastic cells in absence of a PD-L1-mediated exhaustion.
Lastly, patient-derived neoplastic B-cells (B-Acute Lymphoblast Leukemia and Diffuse Large B Cell
Lymphoma) could be proficiently eradicated in a xenograft mouse model by DART-armed cytokine
induced killer (CIK) cells.
Collectively, patient tailored DART exposures can result in the effective elimination of CD19 positive
leukemia and B-cell lymphoma and the association of bispecific antibodies with unmatched CIK cells
represents an effective modality for the treatment of CD19 positive leukemia/lymphoma.
KEYWORDS
B-cell malignancies;
bispecific antibodies; CIK
cells; DART CD19xCD3; PDTX
Key points
 CD19xCD3 DART antibodies arm CD4 and CD8 cyto-
toxic cells to eradicate all CD19C lymphoproliferative
disorders
 Armed CD19xCD3 DART cytokine induced killer cells
can be used as universal donor cells to treat B cell
neoplasms
Introduction
The therapeutic successes achieved in the last decades in the treat-
ment of B-cell lymphoproliferative disorders are compelling.1-6
Nevertheless, oncologists face exceeding challenges in achieving
prolonged responses and cancer eradication.7-10 Novel immuno-
therapies have proven to complement standard chemotherapy-
based approaches.11-15 Impressive results have been reported using
engineered T-cells (CAR T-cells),16 bispecific antibodies (bsAbs)
and checkpoint inhibitors in the treatment of refractory/aggressive
acute B-cell lymphoblastic leukemia (B-ALL) and other lympho-
proliferative disorders.2,17
Among these innovative approaches, bispecific antibodies
represent an exciting development, because they can be deliv-
ered off the shelf to larger cohorts of patients. Blinatumomab, a
bispecific T-cell engager (BiTE) redirects T lymphocytes -
irrespective of their TCR specificity- against B-cells. First
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approved to treat Philadelphia chromosome-negative precursor
B-cell ALL, blinatumomab is remarkably effective in adult B-
ALL,18,19 leading to clinical remission (CR) or CR with partial
hematological recovery (CRh) in relapsed/refractory ALL.20
BiTe-CD19xCD3 has also shown to be promising in pretreated
patients with relapsed/refractory NHL,21 although resistant
phenotypes may emerge.22,23 Since Blinatumomab treatment
can be technically demanding and inconvenient for the
patients, structural improvements to improve stability, unfa-
vorable pharmacokinetics, and potential immunogenicity are
desirable.24-26
Dual Affinity Re-Targeting molecules (DARTs) are flexi-
ble bsAbs-based platforms with improved stability, good
heavy and light chain pairing and excellent preservation of
the affinity against their target epitopes.27,28 Their modular
design has allowed for the rapid generation of specific DART
targeting unique cancer epitopes,28,29 including CD19.
Although CD19xCD3 DARTs may have favorable features
compared with blinatumomab29 (additional stabilization
through a C-terminal disulfide bridge, high stability in both
formulation buffer and human serum), an in-depth under-
standing of the mechanisms leading to optimal DART-medi-
ated T-cell activation and generation of potent effector cells
in vivo are highly desirable to minimize the fraction of non-
responder patients.
Several questions need to be addressed: i) the potential for
an intrinsic resistant phenotype of CD19C tumor cells; ii) the
immune characteristics of cancer patients at the time of treat-
ment and during disease progression; iii) the ideal T:B and
CD4:CD8 ratio for optimal effector function in vivo; and iv)
any potential impairment in proliferation, the occurrence of
premature T-cell exhaustion, defects in cytotoxic machinery or
an altered balance between killing effector memory cells and
central memory cells that maintain the effector pool.
Here, we investigated the effects of CD19xCD3 DART using
primary neoplastic B-cells and in vitro and in vivo models. Our
findings demonstrate that CD19xCD3 DART efficiently acti-
vates both CD4C and CD8C donor T-cells that can eliminate
autologous leukemia/lymphoma cells in all patients. We proved
that cytokine-induced killer (CIK) cells and CD19xCD3 DART
can control and/or eradicate patient-derived tumor xenografts
(PDTX) from chemo-refractory B-ALL and diffuse large B-cell
lymphoma (DLBCL) patients. In summary, the combination of
universal effector cells and CD19xCD3 DART represents a
promising and powerful strategy to treat human B-cell
neoplasms.
Material and methods
DART proteins and other materials
The CD19xCD3 DART protein was constructed as described.29
The control DART molecule, 4420xCD3, in which the variable
domain sequences of the anti-fluorescein mAb 4–4–2030 repla-
ces the CD19 DART protein arm, was engineered in a similar
manner. DARTs were expressed transiently in CHO-S cells27
and purified to homogeneity by using protein A. Dexametha-
sone (Sigma) and ibrutininb (Selleckchem) were used in in vitro
assays.
Cell lines
The human cell MEC-1 (chronic B-cell leukemia),31 Daudi
(Burkitt’s lymphoma) and THP1 (acute monocytic leukemia)
were cultured in complete RPMI 1640 (Invitrogen Life Tech-
nologies, Gaithersburg, MD) supplemented with heat-inacti-
vated 10% fetal calf serum (FCS) and 1% penicillin/
streptomycin (GIBCO, Invitrogen, Milan, Italy).
Patients
Samples were obtained from patients hospitalized within the
Division of Hematology and Cell Therapy of Ospedale Mauri-
ziano or the Division of Hematology, San Giovanni Battista,
University of Torino, Italy, after informed consent in accor-
dance with the University and State regulations and approved
by the Ethical Hospital and University committees (0081521).
Diagnoses were reached according to the World Health Orga-
nization classification. Patients were selected based uniquely
on CD19 expression, to widen the spectrum of B-cell malig-
nancies. Characteristics of patients are shown in Table 1.
Generation of CIK cells
PBMC were cultured at 2 £ 106 cells/ml in complete RPMI
1640 medium supplemented with 1000 U/ml of IFN-g (Pepro-
Tech Inc., Rocky Hill, NJ). After 24h of culture CD3 mAb (100
ng/ml OKT3; Miltenyi Biotec, Calderara di Reno, Italy) and
300 U/ml of IL-2 (Proleukin; Chiron, Munich, Germany) were
added to the cell culture. Medium was replaced (1/2) with fresh
medium supplemented with IL-2 every 3rd day. Phenotypic
analysis was performed at the end of 3–4 weeks of culture.
Flow cytometric analysis
Cell surface molecules expression was determined by multicol-
our flow cytometry, using a panel of monoclonal antibodies
(see supplemental data).
B-cell depletion assay
Mononuclear cells were isolated from bone marrow (BM) or
peripheral blood (PBMC) by Ficoll-paque gradient (Pharmacia,
Uppsala, Sweden) and re-suspended in complete RPMI 1640 at
1£ 106/ml. B-ALL were cultured in complete Iscove’s Modified
Dulbecco’s Media (Invitrogen Life Technologies).
4420xCD3 or CD19xCD3 DART (0,1 ng/ml to 10 ng/ml)
were maintained for 6 d. Viable cells was determined by trypan
blue staining. The fold changes were calculated as described in
supplemental data. In repetitive cell cultures of primary B-CLL,
CD19xCD3 DART-expanded T-cells were re-challenged with
autologous purified CD19C B- cells (1 £ 106/ml).
Proliferation
The proliferation of autologous T-cells was evaluated by flow
cytometer. Labeled PBMC with CFSE (see supplemental data)
were plated at 1 £ 106/ml in RPMI 1640 and cultured with or
without CD19xCD3 or 4420xCD3 DART for 6 consecutive
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days. At the end of cultures, CD19 B-cells were monitored and
proliferation of redirected T-cells was quantified on viable cells
as % of CD4CCSFE¡or CD8CCSFE¡ cells.
Cytokine production
Measurement of IFN-g, TNFa, IL-10, IL-6, IL-4, IL2 in tissue
culture supernatants was performed using available ELISA set
(CBA assay) according to the manufacturer’s recommenda-
tions. Supernatants were collected from cultured cells at day 6.
The results were interpolated from a standard curve using
recombinant cytokines and expressed in pg/ml.
In vivo efficacy studies
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were bred within
the Molecular Biotechnology Center (MBC) Animal Resource,
under strict specific and opportunistic pathogen free (SOPF)
conditions. Patient Derived Tumor Xenograft (PDTX) were
established as described 32 and mice were treated with CIK
with and without DART antibodies (see supplemental data).
Mouse studies were executed in accordance to the animal
experiment design within the project entitle “ Analysis of the
molecular aberration of solid tumors and lymphoproliferative
disorders” approved by the Bioethical Committee of the Uni-
versity of Torino (Torino, September 11, 2010).
Magnetic resonance imaging
Whole-body Magnetic Resonance images (MRI) of anesthe-
tized (Zoletil 100 at 20 mg/kg, Rompun at 5 mg/kg.) NSG
grafted mice with B-ALL were acquired on the M2 Aspect 1T
MRI scanner (Aspect Imaging, Shoham, Israel) equipped with
a 30 mm solenoid RX/TX coil. T2-weighted anatomic images
Table 1. Characteristics of patients.
UPN SOURCE WHO 2008 CLASSIFICATION DISEASE STATUS %CD4 at day 0 %CD8 at day 0 %CD19 at day 0
PT# 1 SPL B Splenic Lymphoma (not classified) DGN 2.3 2 92
PT# 2 LN B-CLL DGN N/A N/A N/A
PT# 3 LN B-CLL DGN 21 4.5 74
PT# 4 LN FL R/R (I REL) N/A N/A N/A
PT# 5 LN MCL R/R (I REL) N/A N/A N/A
PT# 6 LN B-CLL UNTREATED 9 3 87
PT# 7 LN FL DGN 50 21 26
PT# 8 PB FL DGN 21.21 4.84 60.55
PT# 9 PB B-CLL UNTREATED 2.99 1.53 91.95
PT#10 PB SMZL UNTREATED 3.66 1.95 55.8
PT#11 PB B-CLL R/R (REF) 1.45 0.37 96.39
PT#12 BM B-CLL R/R (REL) 3.5 6 90
PT#13 PB B-CLL R/R (REF) 2.67 1.98 87.94
PT#14 PB B-CLL R/R (II REL) 0.8 0.5 98
PT#15 LN FL DGN 3.52 0.89 86.26
PT#16 PB B-CLL R/R (I REL) 11.85 9.6 71.33
PT#17 PB B-CLL R/R (III REL) 2.88 2.01 89.14
PT#18 PB MCL DGN 3.26 7.33 85.38
PT#19 PB FL DGN 4.45 1.06 94.76
PT#20 BM B-ALL DGN 3.65 3.16 84.57
PT#21 PB SMZL R/R (REL) 56.55 16.88 12.25
PT#22 PB B-CLL R/R (REL) 0.43 0.22 98.72
PT#23 PB B-CLL UNTREATED 2.28 2.02 88.3
PT#24 PB SMZL DGN
PT#25 PB B-CLL R/R (II REL) 4.52 2.99 91.1
PT#26 PB B-CLL R/R (REF) 11.61 9.8 69.46
PT#27 PB B-ALL DGN 1.33 0.66 72.87
PT#28 BM HCL DGN 11.03 2.64 75.69
PT#29 LN DLBCL DGN 51.75 21.1 16.8
PT#30 BM MCL DGN 16.43 5.38 44.46
PT#31 PB MZL R/R (REF) 2.44 8.06 63.44
PT#32 PB B-ALL DGN 1.52 0.51 94.77
PT#33 PB B-CLL DGN 6 6.13 79.47
PT#34 PB B-ALL DGN 1.04 1.11 90.33
PT#35 PB B-ALL DGN 2.74 2.08 83.98
PT#36 PB B-CLL R/R (I REL) 2.04 3.59 87.89
PT#37 PB B-ALL R/R (REF) 2.94 5.82 84.63
PT#38 BM B-CLL R/R (II REL) 1.4 0.7 98
PT#39 PB FL DGN 28.65 4.38 41.99
PT#40 PB B-CLL/Richter transformation R/R (REF) 0.61 0.26 98.46
PT#41 PB B-CLL R/R (I REL) 11.63 11.15 74.09
PT#42 PB B-CLL DGN 6.06 2.23 88.53
PT#43 PB blastoid MCL DGN 2.28 0.91 81.01
PT#44 BM B-ALL DGN 0.27 0.39 98.08
PT#45 PB MZL R/R (II REL) 11.1 4.58 66.24
PT#46 BM B-CLL DGN 5.61 3.29 69.28
PT#47 PB B-CLL DGN 5.32 3.17 87.19
PT#48 PB B-CLL DGN 19.72 2.1 66.9
PT#49 BM B-CLL DGN 4.27 2.07 79.35
PT#50 PB MCL DGN 1.28 1.16 96.74
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were acquired with a Fast Spin Echo sequence (TR/TE/NEX
2800 ms/44 ms/2) covering 21 slices (thickness 1 mm, gap
0.1 mm, Field of View 100 mm and Matrix Size 256, for an in-
plane resolution of 391 mm). Images were manually segmented
using 3D Doctor Able software to calculate the volume of target
organs for 3D rendering.
RNA-Seq library preparation and RNA-Seq analysis
and Gene expression profile analysis
RNA-seq was performed as described previously 32(see supple-
mental data). Hierarchical clustering and dendrogram were
generated by means of the GenePattern2.0 suite. Gene set
enrichment analyses were performed by means of GSEA
software.33
Statistical analysis
Statistical analysis was performed by Prism software, version
5.0 (GraphPad Software, San Diego, CA). Data are reported as
means § SD or means only, as described in figure legend (see
supplemental data).
Results
In vitro response to CD19xCD3 DART stratifies B-cell
lymphoproliferative disorders in 2 distinct subsets
To assess the activity of CD19xCD3 DART against primary
lymphoproliferative cells, we selected 50 na€ıve or treated
patients (25 B-chronic lymphocytic leukemia, 7 B-ALL, 6 follic-
ular lymphoma, 5 marginal zone lymphoma, 5 mantle cell lym-
phoma, 1 hairy cell leukemia, 1 patient with splenic lymphoma
NOS). The percentage of B-cells ranged from 12.25% to 98.72%
(median 85.01%) with a broad B:T ratio (0.16 to 151.87; median
12.26). Relevant clinical and phenotypic characteristics are
reported in Table 1.
When unfractionated samples were cultured with increasing
concentrations of CD19xCD3 DART (from 0.1 ng/ml to 10 ng/
ml) or control DART (4420xCD3) or in supplemented
medium, a decrease in CD19 cells was observed only in the
CD19xCD3 DART treated samples (Fig. 1A). Percentage of
CD19C B-cells (killing percentage) correlated with the B:T ratio
at day 0 (rs D »¡0.73, p D 9.8 £ 10¡9). As the extent of B-cell
depletion observed at 10 ng/ml DART was variable (mean of
17.88% CD19C B-cells), samples were stratified according to
the CD19 mean value (at day 6, < or >17.88%). Patients with
CD19 B-cell ratios greater than 17.88% were defined as “slow
responders” and those with less than 17.88% as “fast respond-
ers." Fast responders showed a significant reduction in B-cells
(Fig. 1B top panel), compared with slow responders or controls
(Fig. 1B bottom panel). Similar results were obtained grouping
patients according to the CD19C percentage at day 6 and focus-
ing on upper (25th) and lower distribution (75th). A representa-
tive dot plot of a fast responder (PT# 19 top panel) and slow
responder patient (PT# 15 bottom panel) is shown (Fig. 1C).
CD19xCD3 DART elicited a robust expansion of both autol-
ogous CD4C and CD8C autologous lymphocytes (Fig. 1D–1G,
S1-A), with an increase in the absolute numbers of T-cells
(Fig. 1E) and a net reduction/complete depletion of B-cells. We
observed a less noticeable CD4C and CD8C expansion among
slow responders (Fig. 1F). Moreover, the absolute numbers of
CD4C cells (Fig. 1G left panel), but not that of CD8C, increased
in the slow responders compared with controls (Fig. 1G right
panel), suggesting that CD8C effector T-cells are required for an
effective ablation of the target cells. Since the percentage of
CD4C and CD8C T-cells at day 0 was substantially higher within
the fast responders’ group (CD4: 11.04 § 14.96 vs 4.36 § 5.67
and CD8: 5.33§ 5.4 vs 1.62§ 1.63 with pD 0.03 for CD4C and
p D 0.0009 for CD8C, respectively), we correlated the percent-
age of CD19C cells at day 6 with CD3C T-cells (CD4C and
CD8C) at day 0 (rs D ¡0.3237146, p»0.02), suggesting that
CD19xCD3 treatment is affected by the initial number of CD3C
T-cells. This was corroborated by designing a random effect
mixed model allowing for subject dependent effects (LRT: p D
0.0008605 ).
Next we tested whether CD19xCD3 DART treated T-cells
maintained their specificity, avoiding off target effect. We
mixed CD19xCD3 DART or control-challenged T-cells with
CD19C MEC-1 cells at different effector: target (E:T) ratios.
Negligible lysis of MEC-1 cells was observed at lower ratio (E:T
0,62:1: 17.95 § 11.38%), but lysis was seen at higher E:T ratios
(91.3 § 4.8% at 20:1 P D < 0.0001, Fig. S1-B), an effect that
could be blocked by a neutralizing anti-CD19 Abs (Fig. S1-C)
and in part linked to membrane bound CD19xCD3 DART
molecule (Fig. 1S–D) Conversely, minimal cell lysis was seen at
the highest E:T ratios (21.93 § 13.20) using CD19 negative tar-
get-cells (THP1).
Total B-cell eradication can be achieved in both fast
responder and slow responder patients
Since treatment of slow responders with CD19xCD3 DART
could lead to a partial eradication, we assessed their T-cell
expansion capacity in randomly selected patients, demonstrat-
ing that CFSE labeled CD4C and CD8C cells effectively prolifer-
ate in the presence of CD19xCD3 DART (Fig. 2A left and right
panel) and that prolonged exposures (12 days) to CD19xCD3
were associated with their robust expansion (Fig. 2B middle
and right panel) and complete eradication of neoplastic B-cells
(5 B-CLL, 1 B-ALL, Fig. 2B left panel). In very poor responders,
a further challenge (on day 14) with the CD19xCD3 DART was
necessary (Fig. 2C, left panel), leading to global T-cells expan-
sion with a rapid CD4C growth (Fig. 2C, middle panel) and a
more progressive CD8C cells expansion (Fig. 2C, right panel).
Next, we tested whether the exposure to dexamethasone
could modulate the efficacy of CD19xCD3 DART. As cortico-
steroids are used to prevent cytokine release syndrome (CRS),
we pre-treated PBMC with dexamethasone and then we added
the DARTs. The pretreatment blocked the expansion of autolo-
gous T-cells and the eradication of neoplastic B-cells (DART
3 § 4.9 versus DART C dexametasone 80.84 § 8.85, Fig. 2D,
left panel). Conversely, when we first treated the PBMC with
DARTs and then added the dexamethasone, we did not observe
any loss of the activation of autologous T-cells and the
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Figure 1. CD19xCD3 molecule mediates autologous CD19C B-cells depletion and expansion of T-cells in vitro. (A) PBMC from PB, BM, spleen or lymph node (nD 50) were
incubated for 6 d alone, with 4420xCD3 or with CD19xCD3 DART (0.1ng/ml, 1ng/ml and 10ng/ml). The percentage of CD19C was evaluated by flow cytometry on viable
cells. The horizontal bars indicate the median value. P < 0.001. (B) The fold change of B-cells was determined at day 6 as the ratio between the absolute number of
CD19C cells in CD19xCD3 DART cultures and CD19C cells cultured with medium alone. The graphs represent the fold decrease of CD19C in fast responders (top panel,
n D 23) and in slow responders (bottom panel, n D 8). The fold changes of fast responders and slow responders at 10 ng/ml were 0.018 § 0.04 and 1.0 § 0.83  P <
0.001. (C) Flow cytometry of a representative fast (top panel) and slow responder patient (bottom panel). (D) The percentage of CD4C (left panel) CD8C (right panel) of
fast responder patients (n D 37). The horizontal bars indicate the median value. (P < 0.001; CD4C from 11.04 § 14.96 at day 0 to 58.07 § 19.11, CD8C from 5.33 §
5.4 to 30,24 § 19,31 at day 6). (E) The fold change of T-cells was determined as the ratio between absolute number of CD4C or CD8C cells in CD19xCD3 DART cultures at
day 6 and at day 0. The fold changes of fast responders CD4C were 7.84 § 5.9 (left panel) and CD8C 7.09 § 7.6 (right panel, n D 23). P < 0.01, P < 0.001. (F) The
percentage of CD4C (left panel) CD8C (right panel) of slow responder patients (n D 13). Horizontal bars represent the median values (CD4C changed from 4.36 § 5.67 at
day 0 to 22.63§ 21.47 and CD8C from 1.62§ 1.63 to 6.62§ 7.69). P < 0.05 and P < 0.01. (G) The fold change of T-cells was determined as the ratio of absolute num-
ber of CD4C or CD8C cells in CD19xCD3 DART cultures between day 6 and day 0. The fold changes of slow responder CD4C were 6.39§ 5.56 (left panel) and CD8C 2.13§
1.66 (right panel, n D 8). P < 0.05 Student’s t test.
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eradication of neoplastic B-cells occurred (Fig. 2D middle
panel). Similarly, T-cells of ibrutinib-treated CLL patients were
functional once challenged with the bsAbs in the absence of the
TKi (Fig. 2E). Interestingly, CD8C cells of ibrutinib-treated
patients were more efficient effectors than those of na€ıve
patients (treated 41.41 § 11.13 vs. untreated 24.10 § 19.95).
CD19xCD3 DART promotes T-cell activation and
differentiation
To define the mechanisms leading to DART-mediated T-cell
activation, we first assessed the cytokine levels of supernatants
triggered by CD19xCD3 DART or control DART-cells. High
Figure 2. (For figure legend, see page 7.)
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levels of IFN-g, TNF-a, IL10, and IL6 were produced after
DART activation (Fig. S2-A)34,35 by T-cells which rapidly upre-
gulated CD25 surface membrane receptors (Fig. S2-B). Acknowl-
edging that CD4CCD25C T-cells can be negative regulators, we
quantified CD4CCD25CFoxP3C among DART activated T-cells,
demonstrating only seldom and minor expansions (Fig. 3A).
Conversely, CD4C and CD8C co-expressed PD-1 (Fig. 3B), a
marker linked to either activation or T-cell exhaustion.36 Then,
when PD-1C and PD-1¡ cells were isolated and co-cultured with
CD19C MEC-1 target-cells, they displayed similar efficacies
(Fig. 3C), suggesting that the PD-1 expression was not linked to
a dysfunctional phenotype.
Immunophenotypically DART activated CD4C and CD8C
displayed a central and effector memory phenotype (Fig. 3D
left and right panel, P<0,05 and Fig. 3E left and right panel),
while terminally differentiated effector memory subsets
(TEMRA CD45RACCD62L¡) represented a small fraction.
Similar findings were seen in slow responders.
Interestingly, CD8C expressed higher levels of granzyme
B than CD4C T-cells (Fig. 3F) and lesser CD4C (mean: 4.81
§ 4.29) and CD8C (mean: 35.63 § 11.76) granzymeC cells
were observed in slow responders (CD4C mean: 12.78 §
5.48; CD8C mean: 64.04 § 18.6). We also noted that the
DART-mediated responses could change over time, as docu-
mented in a patient that, during the course of the disease,
displayed both phenotypes (Fig. 3G, upper and lower
panel).
To gain further insight into the mechanisms related to the
functional changes in T-cells after DART-mediated activa-
tion, we performed transcriptomics analyses of purified cells
prior and after CD19xCD3 DART exposure. Unsupervised
analysis showed that CD19xCD3 DART-activated CD4C and
CD8Ccells clustered together and displayed high levels of
genes expressed by memory, Th1 and cytotoxic T-cells
(Fig. 3H to L). CD19xCD3 DART CD4 cells were positive
for ThPOK, GATA3, Myb and RUNX1 transcription factors,
known to control the CD4 phenotype, and STAT1, STAT3, 4
and 5. STAT1 regulates the expression of T-Bet which in
conjunction with STAT4 leads to the upregulation of
RUNX3. These findings were also in agreement with the
increased expression of IFN-g by CD19xCD3 DART acti-
vated CD4 cells (Fig. 3L).
Both CD4C and CD8C cells differentiate into effector
cytotoxic elements and maintain their cytotoxic capacity
upon consecutive challenges
Following CD19xCD3 DART, purified CD8C cells were rechal-
lenged with CD19C cells (Fig. 4A) and demonstrated a robust
cytotoxic response with or without further addition of the
CD19xCD3 DART. Conversely, purified CD4C T-cells dis-
played a minor cytotoxic capacity in the absence of DART (E:T
ratio 20:1: 41.44 § 23.34) but the addition of CD19xCD3
DART improved target elimination (Fig. 4A).
To test whether CD4C and CD8C cells were concomitantly
required for the generation of effector cytotoxic cells, purified
CD4C or CD8C cells at day 0 were mixed with autologous
B-cells in the presence of CD19xCD3 DART. Under these con-
ditions, CD8C were effective in killing the target T-cells, while
CD4C cytotoxic activity was absent (Fig. 4B). Overall, these
data demonstrate that the generation of CD4C cytotoxic cells
requires the concomitant presence of the CD8C elements.
Next, to test whether CD19xCD3 DART-mediated T-cells
could be maintained over time, we selected a responder patient
(PT#6) whose DART-activated T-cells were repeatedly chal-
lenged with freshly isolated autologous purified CD19C (1:5 ratio
E:T, Fig. 5A). This protocol was repeated up to 7 consecutive
times, demonstrating that DART-activated cells could maintain
their cytotoxic capacity and be able to eradicate neoplastic B-cells
for up to 7 consecutive re-challenges (Fig. 5B, lower panel). Con-
versely, untreated or 4420xCD3 DART-challenged T-cells were
ineffective (Fig. 5B). CD19xCD3 DART re-stimulation was asso-
ciated with a robust T-cell expansion (Fig. 5C), high levels of
IFNg and TNFa (Fig. S3-A) and by accumulation of granzyme
B-positive CD4C and CD8C cells (Fig. 5D).
CD19xCD3 DART exhibits antitumor effects in xenograft
mouse models
To extend our ex vivo data, we studied 2 humanized mouse
models bearing Patient Derived Tumor Xenograft (PDTX).
Since human PMBC lead to severe graft vs. host disease
(GVHD) in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice,37 we applied an alternative strategy taking advantage
of human cytokine-induced killer (CIK) effector cells. CIK
Figure 2. (see previous page) CD19xCD3 DART induces proliferation of CD4C and CD8C cells and leads to total eradication of neoplastic B-cells in fast responder and slow
responder patients. (A) CFSEC PBMC of fast responder (nD 8) or slow responders (nD 4) patients were cultured in media, with 4420xCD3 or CD19xCD3 DART at 10 ng/ml,
for 7 d. The graphs show the percentage of dividing CD4C (white column) or CD8C (gray column) of responder (left panel) or slow responder patients (right panel, CD4C:
77.08 § 31.82 vs 76.73 § 22.64 and CD8C: 88.23 § 14.24 vs 66.74 § 25.18). Statistical significance: P < 0.05,P < 0.01, P < 0.001. (B) PMBC from slow responder
patients (nD 6) were cultured alone (&), with 4420xCD3 (~) or CD19xCD3 at 10ng/ml () for the indicated number of days. The percentage of CD19C B-cells (left panel),
CD4C (middle panel) or CD8C T-cells (right panel) is presented. Asterisks represent statistical significance of CD19C, CD4C or CD8C T-cells cultured with CD19xCD3 DART
vs untreated (B-cells: from 50.84 § 34.36 at day 6 to 1.88 § 2.18 at day 12, CD4C from 32.91 § 23.64 at day 6 to 59.30 § 22.38 a day 12; CD8C: from 8.14 § 9.21 at day
6 to 26.73 § 12.82 at day 12; P < 0.05P < 0.01,  P < 0.001) (C) PMBC of a single slow responder patient were cultured either alone (&), with 4420xCD3 (~) or
with CD19xCD3 () at 10 ng/ml up to day 13 (CD19C cells from 71.10% at day 0 to 40.37% day 6). On day 14 cultured cells were harvested and re-challenged with DART
at 10 ng/ml. At day 6, 13, 21, 25 the percentage of viable CD19C (left panel), CD4C (middle panel) or CD8C (right panel) cells was determined. The percentage of CD4C
increased from 15.44% at day 0 to 45.86% at day 13, 44.22% at day 21 and 40.84% at day 25. The percentage of CD8C increased from 3.21% at day 0 to 8.77% at day 13,
30.81% at day 21 and 46.71% at day 25. (D) Left panel: PBMC from B-CLL patients were cultured with dexamethasone at 10¡5M for 3 d and then 4420xCD3 or CD19xCD3
DART at 10 ng/ml were added for 4 d. In control cultures, PBMC were incubated for 7 d either alone, with 4420xCD3 at 10ng/ml or CD19xCD3 DART at 10 ng/ml. The per-
centage of CD4C (white column), CD8C (gray column) and CD19C (black column) are depicted. The treatment with the corticosteroid blocked the expansion of CD4C
(DART-treated 63.9 § 11.3 vs. DARTC dexametasone 11.47 § 5.08) and CD8C (DART-treated 25.67 § 16.9 vs. DARTC dexametasone 0.7 § 0.5) cells and impaired the
eradication of neoplastic B-cells (DART 3 § 4.9 vs. DARTC dexametasone 80.84 § 8.85). Right panel: PBMC were cultured with 4420xCD3 or CD19xCD3 DART at 10 ng/ml
for 3 d and then dexamethasone at 10¡5M was added for 4 d. Dexamethasone treatment after DART led to activation of autologous T-cells (CD4C: 67.9 § 17.8 and CD8C:
25.34 § 16.45) and the eradication of the neoplastic B-cells (1.59 § 2.14, P < 0.05P < 0.01). (E) PBMC from B-CLL patients under treatment with ibrutinib at thera-
peutic dose (n D 5) were incubated for 6 d either alone, with 4420xCD3 or with CD19xCD3 DART at 10ng/ ml. Percentage of CD4C (white column), CD8C cells (black col-
umn) and CD19C (gray column), were determined by flow analysis (P < 0.01,  P < 0.001) (right panel).
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cells are major histocompatibility complex (MHC) unre-
stricted cytotoxic cells 38 and they do not mediate relevant
GVHD reactions.39
We first showed that the CD19xCD3 DART could effec-
tively redirect human CIK cells from normal subjects and from
patients against tumor B-cells in vitro (Fig. S4-A,-C). In vivo,
the engraftment of CD19CCD34C B-ALL cells leads to a rapid
and massive infiltration of both lymphoid (spleen, bone mar-
row, etc.) and parenchymal organs (liver, kidneys, lungs etc.)
and a blood stream invasion in all injected mice (Di Giacomo,
personal communication). To evaluate the antitumor activity
of the CD19xCD3 DART and CIK cells, NSG mice were
Figure 3. The effect of CD19xCD3 DART on proliferation and differentiation of autologous T-cells. (A) The percentage of regulatory T-cells was determined analyzing
Foxp3 and CD25 expressions within the CD3C/CD4C cell subset (n D 10). (B) Expression of PD1 on CD4C (mean: 73.09 § 17.73, right panel) and on CD8C (mean: 51.45 §
26.27, left panel) T-cells (n D 12). Horizontal bars indicate the median value (P < 0.05, P < 0.01, P < 0.001). (C) Purified PD1¡ (solid black line) and PD1C (dotted
gray line) cells (n D 3) from CD19xCD3 DART culture were co-cultured with CFSE-labeled MEC1 cells either alone (circles), in the presence of 4420xCD3 (triangles) or the
CD19xCD3 (squares) DART (10 ng/ml). The cytotoxicity was determined at different ratio E:T by flow cytometric analysis after 16 hours of incubation (90.89 § 4.6 for
PD1¡ and 93.43 § 0.4 for PD1C T-cells at 20:1 E:T and 33.94 § 13.35 for PD1¡ and 31.06 § 7.96 for PD1C T-cells at 0,62:1 E:T). Comparisons between CD4C or CD8C
untreated or 4420xCD3 vs. CD19xCD3 DART treated were statistically significant (P< 0.05, P< 0.01,  P< 0.001). D-E) Subset distribution of na€ıve (CD45RACCD62LC
black), central memory (CD45RA¡CD62LC gray), effector memory (CD45RA¡CD62L¡ diagonal lines), terminal differentiated effector memory (CD45RACCD62L¡ white) in
CD4C (left panel) and CD8C T-cells (right panel) of fast responder (D, n D 8) and slow responder patients (E, n D 4). (F) Expression of granzyme B in CD4C of fast
responder (n D 6, white column) and slow responder (n D 5, white column with diagonal lines) patients and in CD8C of fast responder (gray column) and slow responder
(gray column with diagonal lines) patients (P < 0.05, P < 0.01). (G) Profile of granzyme B expression in CD4C (left panel) and CD8C T-cells (right panel) of the same
patient (#22) during the course of disease. Dot plots show representative flow cytometric data in a slow responder phase (upper panel) and in a fast responder phase of
the disease (lower panel). (H) Unsupervised analysis of enriched control and DART activated CD4C and CD8C cells demonstrated that both CD4C and CD8C cells after
DART engagement cluster together. Spearman correlation was used as a distance metric for hierarchical clustering of the samples and genes. (I) DART induced activation
leads to higher expression of cytotoxic genes (enrichment confirmed by GSEA analysis) in DART activated CD4C and CD8C cells vs control (p-value D 0.0002,FDR D
0.001). GSEA analysis (pre-ranked) was performed using log2 fold-change of all genes between DART vs Control (Red: high, Green: low). (J) GSEA analysis between DART
vs Control (log2fold change of all genes as the metric for GSEA pre-ranked) shows an enrichment for both memory T-cell associated and Th1 left panels) and NK associ-
ated genes (right panels). (K) Activated CD4C and CD8C DART cells display high levels of master regulators and (L) IFN-gamma transcripts.
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inoculated with a lethal dose of B-ALL (1 £ 106, i.v.) and then
treated with serial doses of CIK cells (3 £ 106, i.p.). All mice
injected with CIK had no sign of GVDH. CIK mice were ran-
domized to receive either vehicle or CD19xCD3 DART
(Fig. 6A). By day 28, untreated mice showed a fatal leukemic
phenotype. Meanwhile, mice treated with CIK cells displayed a
partial response. Conversely, the combination of CIK and
DART led to a robust anti-leukemia response (p D 0.0460 vs.
Figure 3. (Continued).
Figure 4. CD19xCD3 DART induces differentiation of CD4C and CD8C cells into efficient cytotoxic effectors T-cells (A) Purified CD4C (solid black line) and CD8C (dotted
black line) T-cells (n D 6) from CD19xCD3 DART culture were co-cultured overnight with CFSE-labeled MEC1 cell line either alone (circles), in presence of 4420xCD3
(squares) or CD19xCD3 (diamonds) DART at 10 ng/ml. The cytotoxicity was determined at different ratio E:T by flow cytometric analysis after 16 hours of incubation. P <
0.05, P < 0.01,  P < 0.001 at 2-tailed student t test. All comparisons between CD4C untreated vs. CD19xCD3 DART and CD8C untreated or 4420xCD3 vs. CD19xCD3
DART were statistically significant. (B) Purified CD4C and CD8C T-cells isolated from PBMC (n D 5) were separately co-cultured with autologous purified CD19C either
alone, with 4420xCD3 or CD19xCD3 DART at 10 ng/ml for 6 d. At day 6, the percentage of CD4C (white column), CD8C (gray column) and CD19C (white column with diag-
onal) was determined (day 0: 67,51 § 23,23 day 6: 1,09 § 2,2 with purified CD8C cells).
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CIK-treated mice Fig. 6B). All treated mice were alive at day 40
and were therefore killed to determine the extent of the
response. The superior antitumor response of DARTCCIK-
treated mice was associated with a decreased fraction of CD19C
blood circulating cells (Fig. 6C) and virtually undetectable
leukemic cells at autopsy (Fig. 6D). On the other hand, CIK-
treated mice displayed infiltrating leukemic cells in the spleen,
bone marrow, liver, kidneys and lungs. Both CIK-treated and,
to a lesser extent, DARTCCIK-treated mice showed some infil-
trating cells within the bone marrow (Fig. 6E). By flow
Figure 5. CD19xCD3 DART induces T-cell expansion and preserves cytotoxic capacity upon repeated challenges.( A) Schedule of repetitive culture of PBMC derived from a
patient with CLL. PBMC were cultured with IL2 (20U/ml) and IL7 (5 ng/ml) and analyzed by flow cytometry. Fresh autologous CD19C cells (E:T ratio 1:5) were added as
indicated (black arrows). (B) Representative flow cytometric dot plots of CD19C and CD8C cells after the first (day 8), fifth (day 36), and last (day 58) challenges with autol-
ogous B-CLL cells. (C) Absolute number of CD4C (white column), CD8C (gray column) and CD19C (black column) calculated at the end of every challenge. (D) Representa-
tive dot plots of intracellular Granzyme B expression as evaluated by flow cytometry at day 17 (III challenge). Values indicate the percentage of CD4C/granzyme-BC
(upper panel) and the CD8C/granzymeBC population (lower panel).
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cytometry, CIK cells were undetectable in the peripheral blood
for up to 21 days, and then increased in CIK-treated as com-
pared with CIKCDART mice (Fig. 6F), but at autopsy, CIK
cells were readily detected in many organs (Fig. 6G).
We also studied a PDTX model from a chemo-refractory
leukemic triple-hit DLBCL in which engrafted mice (s.c. 1 £
106) die within 3 weeks post challenge (Fig. 7A). NSG mice
were injected with a single bolus of CIK cells (i.p. 5 £ 106)
before the inoculation of the lymphoma cells (s.c.). Mice were
then treated bi-weekly with i.p. doses of CIK and CD19xCD3
DART (5 on/2 off for 7 wks, Fig. 7A) for 5 consecutive weeks
and then CD19xCD3 DART only for 2 additional weeks.
Tumor masses were readily detectable at day 10 in controls
and progressively enlarged over time (Fig. 7B). Conversely,
CIKCDART treatment suppressed tumor growth, leading to
an improved overall survival (p D 0.0047, Fig. 7C). Two of 4
Figure 6. CD19xCD3 DART inhibit B-ALL patient derived tumor growth in NSG mice (A) Treatment schedule. NSG mice were inoculated with 1 £ 106 B-ALL cells (i.v)
and treatment was initiated at day18 (mean spleen volume 460 mm3). CIK cells (3 £ 106 cells/mouse) were infused i.p. once a week. CD19xCD3 DART (1mg/mouse)
was injected (i.p.) daily. This protocol was repeated for 6 consecutive weeks. (B) Determination of spleen volume by MRI. Spleen volume of untreated mice (black line)
or mice treated with CIK cells (dotted line) or with CIK cells C CD19xCD3 DART (gray line) was monitored once a week from day 0. Values correspond to mean § SD
(p < 0.05). (C) Mice were bled weekly and circulating human CD45CCD19CCD34C cells of untreated mice (black line), of mice treated with CIK cells (dotted line) or
with CIK cells C CD19xCD3 DART (gray line) were analyzed by flow cytometry (P < 0.05, P < 0.001). (D) Representative MRI scans from untreated (left), CIK (mid-
dle) or CIK plus CD19xCD3 DART treated (right) mice. The scan of untreated mouse was performed at day 28 (day of euthanasia) and the scan of the treated mice
(CIK cells or CIK cell plus CD19xCD3 DART) was performed at day 35. Spleens are highlighted and indicated by arrows. (E) At autopsy, the mean percentage of human
CD45CCD19CCD34C cells of CIK (white column: spleen 94,65 § 0,9; bone marrow 99,60 § 0,28; liver 31,30 § 5,23; kidney 34,54 § 47,32 and lungs 13,47 § 13,48) or
CIK C CD19xCD3 DART (gray column: bone marrow 28,0 § 31,43) treated mice was evaluated by FACS analysis. Values correspond to the mean § SD. ( P < 0.01;
 P < 0.001). (F) Mice were bled weekly and circulating CD45CCD3C CIK cells of mice treated with CIK cells (dotted line) or with CIK cells and CD19xCD3 DART (gray
line) were analyzed by flow cytometry. Statistical significance was determined by Student’s t-test vs. the untreated control group (P < 0.05). (G) The average percent-
age of CD45CCD3C CIK cells at the end point was evaluated by FACS analysis in the bone marrow, peripheral blood, spleen, liver, kidney and lung in mice treated with
CIK (white column) or CIK and CD19xCD3 DART (gray column). Values correspond to the mean § SD ( P < 0.01).
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mice of the CIKCDART group were killed for autopsy during
treatment, whereas the other 2 mice were kept for follow up
and were alive without sign of disease at day 45, when they
also were killed for histological analysis. At autopsy, human
CD45CCD19C lymphoma cells were detectable within the s.c.
tumor masses (84.10 § 29.70) or in distal compartments
(spleen: 0.53 § 0.66, bone marrow: 0.29 § 0.344) in untreated
mice (Fig. 7D), while they were absent in CIKCDART ani-
mals. Effector memory CD3C cells were the predominant pop-
ulation in the bone marrow and spleen of these animals
(Fig. 7E left panel),40 whereas a distinct population of central
memory cells was detectable only in the circulating pool
(Fig. 7E right panel).
Collectively these pre-clinical studies demonstrated that
CD19xCD3 DART and CIK cells represent a potentially effec-
tive tool for the treatment of primary human B-cell neoplastic
disorders.
Discussion
We have analyzed the therapeutic efficacy of a new CD19xCD3
DART antibody against a broad spectrum of primary human
B-lymphoproliferative disorders in vitro. Our data demonstrate
that the initial percentage of T-cells closely correlates with
CD19xCD3 DART responsiveness. Nevertheless, effective
responses could be achieved in all patients, regardless of the B-
cell subtypes and the initial number of T lymphocytes. Both
CD4C and CD8C effector cytotoxic cells were proven to be suc-
cessfully generated and CIK cells armed with the bsAbs were
effective in eradicating neoplastic B-cells both in vitro and in
vivo.
Based on the rapidity by which neoplastic cells were elimi-
nated, we stratified patients in “fast responders” and “slow res-
ponders." Although the T-cells of slow responders showed an
initial “dysfunctional phenotype," longer/repetitive exposures
Figure 7. CD19xCD3 DART suppresses DLCL patient derived tumor growth in NSG mice (A) Treatment schedule. NSG mice were inoculated with 5 £ 106 CIK cells i.p. and
after 3 d tissue samples of DLBCL PDTX were implanted (s.c.) on the ventral and/or dorsal regions. CIK cells (5 £ 106 cells/mouse) were infused biweekly for 5 successive
weeks. CD19xCD3 DART (1mg/mouse) was administrated i.p., daily for 7 consecutive weeks. (B) Tumor volume progression was monitored once a week. Values corre-
spond to the mean § SD. Statistical significance was determined by unpaired Student’s t-test vs. the untreated control group ( P < 0.01;  P < 0.001). (C) Kaplan-
Meier analysis of mice engrafted s.c. with DLBCL (black dotted line) and treated with CIK and CD19xCD3 DART (black line). Two CD19xCD3 DART animals without sign of
disease were killed during treatment to histological analysis (black line). (D) The percentage of human CD45CCD19C at the end point was evaluated by FACS analysis in
bone marrow, spleen, and tumor in untreated mice (white column) and in mice treated with CIK plus CD19xCD3 DART (gray column). Values correspond to mean § SD
( P < 0.001). (E) Differentiation stage of CIK cells from mice group treated with CD19xCD3 DART at the end point. The left panel shows analysis performed on CD4C
cells and right panel show analysis performed on CD8C cells.
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to DART resulted in the generation of powerful killer cells indi-
cating that this phenotype was not due to an intrinsic dysfunc-
tion. This is relevant in the case of pluritreated patients,41 who
may have a limited T-cell repertoire, may be less prone to rapid
polyclonal expansion and differentiation toward an effector
phenotype,42 and may be more susceptible to negative regula-
tion by repressor elements.43
It is conceivable that the total number of T-cells as well as
the intracytoplasmic granzyme expression levels represent
bona fide biologic biomarkers predictor of response. Accord-
ingly, the generation of cytolytic autologous CIK cells provide
an alternative and powerful strategy for the debulking of B-cells
neoplasms at early stages of treatment with bsAbs. These may
lead to a rapid control of the disease,44,45 while avoiding high
degrees of T-cell activation that might result in significant
toxicities.
Treatment with CD19xCD3 DART triggers the develop-
ment of CD4C as well as CD8C effector T-cells, in all respond-
ers.46-50 To date, cytotoxic CD4C T-cells have been identified
in specific contexts characterized by a continuous antigen
pressure, such as chronic infection51 or autoimmune disor-
ders.52 The DART-mediated plasticity of mature CD4C
implies that both CD4C and CD8C cooperate in target deple-
tion, promoting strong and sustained anti-tumorigenic activ-
ity. Interestingly, DART-mediated differentiation of CD4C in
killer cells required CD8C. This may due to the soluble factors
and/or co-stimuli and/or direct cell-cell contact. Of note, once
the cytolytic activity of CD4C cells was induced, it could be
maintained over time independently of CD8C cells via repeti-
tive CD19xCD3 DART exposures. This supports a model in
which effectors are defined by their specific functional proper-
ties rather than their immunophenotypes.
The mechanisms driving cytotoxic CD4C effectors remain
unclear and whether cytotoxic CD4C originate from different
CD4C subpopulations or alternatively from a plastic rewiring
remains largely untested.53,54 Our transcriptomic analysis con-
firmed that the activation via CD19xCD3 DART upregulates
Th1 and cytotoxic genes in CD4C cells, in line with the high
levels of STAT4/T-Bet, which are known to sustain Th1 differ-
entiation. Contrary to previous data, Zbtb7b transcripts were
not reduced, demonstrating that bsAb-mediated plasticity does
not change the fate of CD4C cells.53
DART exposure was associated with a reduction of naive
T-cells and a shift toward a TCM and TEM phenotype. In adop-
tive cell-transfer with engineered T-cells, central memory T-cells
rather than effector memory T-cells have a superior antitumor
activity in vivo.55,56 Thus, DART-expanded T-cells with both
TCM and TEM phenotype may provide the optimal mix of effec-
tor subsets to mediate rapid and long lasting antitumor activity
at the same time. In the clinical settings, antitumor activity
could be influenced by CD4CCD25CT regulatory cells (Treg). In
fact, in CD19-CAR T-cells models, transduced Treg can inhibit
CAR-mediated cytotoxicity and cell proliferation.57 Conversely,
DART treatments should not lead to T-cell tolerance in vivo.
Since CD4C and CD8C T-cells can upregulate PD-1, a mole-
cule that is linked to T-cell exhaustion and dysfunction,36 the
role of PD-1 following DART exposure needs to be explored.28
Our data are in line with those of healthy individuals, in which
PD-1 is upregulated by effector memory T-cells without an
exhausted gene signature.58 The DART-mediated PD-1 upre-
gulation most likely fits the model of an “activated” effector
memory phenotype.59
Although bsAbs or engineered T-cells have recently
emerged as powerful biologicals for the treatment of hemato-
logical and other human cancers,60 resistant/escape mecha-
nisms have been observed. These are due to alternative and/or
multifactorial events. These include host related mechanisms
such as poor T-cell expansions/function; conversely in a set-
ting of strong immune responses/inflammatory phenotypes,
tumor cells have been proven to use immune-suppressive
strategies, which can block tumor-lyses/eradication (i.e. over-
expression of PDL-1/PD1, CD4761). Interestingly, tumor cells
may survive in immune privileged sanctuaries (i.e., testis, cen-
tral nervous system), suggesting that compartmentalization
can play a role in a minority of patients.19 However, the most
common escape scenario is linked to the loss of target epito-
pes as result of the loss of peptide recognition due to splice
variants,62 or alternatively to the ablation of tumor surface
antigens.63 Indeed, the loss of CD19 in B-cell neoplasms has
been documented in both ALL as well in CLL patients, with
the latter developing immunoblastic lymphoma.64 In the
case of CD19-relapses of ALL patients, individuals carrying
chimeric fusions (MLL-1) have been found to relapse with
acute myeloid leukemia. A phenomenon linked to either
cell reprogramming, as demonstrated by the presence of iden-
tical Ig rearrangements of both original ALL and recurrent
AML, or de-differentiation of putative uncommitted clones,
bearing however the same translocation.65 Thus, innovative
approaches should be considered to counteract leukemia/lym-
phoma escape mechanisms. These include allogeneic stem cell
transplantation following immune-therapies, which should
improve tumor eradication via anti-leukemia effects, com-
bined usage of bsAbs specifically recognizing different cancer
antigens (i.e., CD123, CD22, CD20 etc.), and/or check point
inhibitors.61 These approaches are currently under investiga-
tion in multiple clinical trials.63
Preclinical studies performed in immunodeficient mice
using bsAbs have tested PBMC effector cells and allogeneic
cell lines as targets.28,29,66,67 Although these models are infor-
mative, they display substantial hurdles to their widespread
use. Here, we investigated the therapeutic potential of
CD19xCD3 DART using PDTX models, that more faithfully
recapitulate ALL and DLBCL, and using CIK cells, which dis-
play low and acceptable alloreactivity in vivo.39 In absence of
GVHD, we observed a strong antileukemic activity as a result
of the high cytotoxic potential of redirected CIK cells and the
effective trafficking of effector cells. Since an effective penetra-
tion of the effectors cells in the tumor environment is
paramount,68 as observed in our DLBCL PDTX model, under-
standing the mechanisms regulating effector trafficking will
ultimately improve clinical performance and the design of
conditioning regimes.
In conclusion, in vitro and in vivo data underscore the
potent anti-tumoral activity of a CD19xCD3 DART for the
treatment of CD19C B-cell disorders. We anticipate that moni-
toring the pre-therapy lymphoid host T-cells together with the
expansion and recruitment of functional effectors can become
informative biomarkers for the design of alternative therapies.
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